CBIZ Investment Advisory Services LLC Boosts Holdings in Moderna, Inc. (NASDAQ:MRNA)

CBIZ Investment Advisory Services LLC grew its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 4,400.0% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,125 shares of the company’s stock after acquiring an additional 1,100 shares during the quarter. CBIZ Investment Advisory Services LLC’s holdings in Moderna were worth $47,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Wilmington Savings Fund Society FSB raised its stake in shares of Moderna by 295.0% during the fourth quarter. Wilmington Savings Fund Society FSB now owns 786 shares of the company’s stock worth $33,000 after acquiring an additional 587 shares in the last quarter. Venturi Wealth Management LLC raised its stake in shares of Moderna by 286.2% during the fourth quarter. Venturi Wealth Management LLC now owns 896 shares of the company’s stock worth $37,000 after acquiring an additional 664 shares in the last quarter. Compass Planning Associates Inc purchased a new position in shares of Moderna during the fourth quarter worth approximately $37,000. Larson Financial Group LLC raised its stake in shares of Moderna by 53.5% during the third quarter. Larson Financial Group LLC now owns 910 shares of the company’s stock worth $61,000 after acquiring an additional 317 shares in the last quarter. Finally, MassMutual Private Wealth & Trust FSB raised its stake in shares of Moderna by 58.2% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,057 shares of the company’s stock worth $44,000 after acquiring an additional 389 shares in the last quarter. 75.33% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts have commented on the stock. HSBC raised shares of Moderna from a “hold” rating to a “buy” rating and set a $58.00 price target on the stock in a research note on Monday, November 18th. Argus cut shares of Moderna from a “buy” rating to a “hold” rating in a report on Wednesday, December 18th. UBS Group cut their target price on shares of Moderna from $96.00 to $78.00 and set a “buy” rating on the stock in a report on Wednesday, February 19th. The Goldman Sachs Group cut shares of Moderna from a “buy” rating to a “neutral” rating and cut their target price for the stock from $99.00 to $51.00 in a report on Wednesday, January 29th. Finally, Leerink Partners cut their target price on shares of Moderna from $31.00 to $27.00 and set an “underweight” rating on the stock in a report on Thursday, January 16th. Four analysts have rated the stock with a sell rating, sixteen have given a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $59.60.

Moderna Trading Up 0.9 %

Shares of MRNA stock opened at $34.62 on Friday. The company’s fifty day moving average price is $35.94 and its 200-day moving average price is $47.37. The stock has a market cap of $13.36 billion, a PE ratio of -3.73 and a beta of 1.86. Moderna, Inc. has a 12 month low of $29.25 and a 12 month high of $170.47.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.